Please assess the completion status of the following clinical trial:

Trial Title: S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of one of the following stages:~  * Newly diagnosed selected stage IIIB disease (T4 lesion due to malignant pleural effusion, any N, M0)~ * Newly diagnosed stage IV disease (any T, any N, M1)~ * Recurrent stage IV disease after prior surgery or radiotherapy~* The following subtypes are eligible:~  * Adenocarcinoma~ * Squamous cell carcinoma~ * Large cell carcinoma~ * Unspecified~* Measurable disease by CT scan, MRI, x-ray, or physical exam~  * Pleural effusions, ascites, or laboratory parameters are not acceptable as the only evidence of disease~ * Not within prior radiotherapy field unless a new lesion is present~ * Not within area of prior surgical resection~* No known brain metastases by CT scan or MRI~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 mg/dL~Hepatic~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* SGOT or SGPT ≤ 2 times ULN~* Alkaline phosphatase ≤ 2 times ULN~* No known acute hepatitis~Renal~* Creatinine ≤ ULN~* Creatinine clearance ≥ 50 mL/min~Cardiovascular~* No significant cardiac disease~* No uncontrolled hypertension~* No unstable angina~* No congestive heart failure~Other~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission~* No active or uncontrolled infection~* No sensory neuropathy ≥ grade 2~* No known human anti-mouse antibodies~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior biologic therapy for NSCLC~* No prior chimeric or murine monoclonal antibody therapy~* No prior cetuximab~Chemotherapy~* No prior systemic chemotherapy for NSCLC~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~* At least 3 weeks since prior radiotherapy and recovered~Surgery~* See Disease Characteristics~* At least 2 weeks since prior thoracic or major surgery and recovered~Other~* No prior gefitinib or other investigational agents that target the epidermal growth factor receptor pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).